Trial reportJournal of affective disorders2015
Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression.
Trial report in Journal of affective disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Appetite measures as correlates of clinical response in mood disorders treated with ketamine: systematic review.Frontiers in nutrition · 2025Pooled it
- Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.The lancet. Psychiatry · 2023Pooled it
- Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.Molecular psychiatry · 2022Pooled it
- Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.Expert opinion on drug safety · 2022Pooled it
- Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2023Review
- Postsynaptic Proteins at Excitatory Synapses in the Brain-Relationship with Depressive Disorders.International journal of molecular sciences · 2022Review
- Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder.Translational psychiatry · 2020Article
- Neurobiological biomarkers of response to ketamine.Advances in pharmacology (San Diego, Calif.) · 2020Review
- Intrinsic Brain Network Biomarkers of Antidepressant Response: a Review.Current psychiatry reports · 2019Review
- Transcriptional changes in response to ketamine ester-analogs SN 35210 and SN 35563 in the rat brain.BMC genomics · 2019Article
- Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.Translational psychiatry · 2017Article
- Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.Journal of affective disorders · 2017Review
- Structural connectivity and response to ketamine therapy in major depression: A preliminary study.Journal of affective disorders · 2016Article
- Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.Current behavioral neuroscience reports · 2015Article
- Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Therapeutic advances in chronic disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundShank3, a post-synaptic density protein involved in N-methyl-d-aspartate (NMDA) receptor tethering and dendritic spine rearrangement, is implicated in the pathophysiology of bipolar disorder. We hypothesized that elevated baseline plasma Shank3 levels might predict antidepressant response to the NMDA receptor antagonist ketamine.
methodsTwenty-nine subjects with bipolar depression received a double-blind, randomized, subanesthetic dose (.5 mg/kg) ketamine infusion. Of the patients for whom Shank3 levels were collected, 15 completed baseline 3-Tesla MRI and 17 completed post-ketamine [(18)F]-FDG PET.
resultsHigher baseline Shank3 levels predicted antidepressant response at Days 1 (r=-.39, p=.047), 2 (r=-.45, p=.02), and 3 (r=-.42, p=.03) and were associated with larger average (r=.58, p=.02) and right amygdala volume (r=.65, p=.009). Greater baseline Shank3 also predicted increased glucose metabolism in the hippocampus (r=.51, p=.04) and amygdala (r=.58, p=.02). LIMITATIONS: Limitations include the small sample size, inability to assess the source of peripheral Shank3, and the lack of a placebo group for baseline Shank3 levels and comparative structural/functional neuroimaging.
conclusionsShank3 is a potential biomarker of antidepressant response to ketamine that correlates with baseline amygdala volume and increased glucose metabolism in the amygdala and hippocampus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.